Optimizer and developer of small molecule drugs that target inflammatory diseases BioCryst Pharmaceuticals announced earlier today that Fred E. Cohen, M.D., D.Phil., has been recruited to the company’s Board of Directors.
“The Board of Directors and Leadership Team of BioCryst are very pleased to have Fred join the Company’s Board,” stated Chairman of the Board of BioCryst, George B. Abercrombie, “Fred brings a wealth of scientific knowledge and business acumen to BioCryst and has been a valuable resource to the organization for several years as both an advisor and as an investor. We look forward to his guidance and insights toward the further success of BioCryst.”
Dr. Cohen joined TPG in 2001 to facilitate TPG’s venture initiatives into life sciences and biotechnology. He currently serves as a Partner and Managing Director at TPG Biotech. In addition, Dr. Cohen has been a faculty member since 1986 of the University of California, San Francisco (UCSF). At UCSF, Dr. Cohen has served as an Internist for hospitalized patients, a consulting Endocrinologist and most impressively as the Chief of the Division of Endocrinology and Metabolism. Most known for his research in the fields of protein structure and the conformational basis of prion disease, Dr. Cohen’s research interests include prion diseases, structure based drug design, computational biology, and heteropolymer chemistry.
Dr. Cohen received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, and an M.D. from Stanford. He completed postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. Also a Fellow of the American College of Physicians and the American College of Medical Informatics, as well as a member of the American Society for Clinical Investigation and Association of American Physicians, Dr. Cohen was elected to the Institute of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008.
Dr. Cohen currently serves on the Board of Directors of Genomic Health, Quintiles Transnational, and on the Boards of several privately held companies.
“Both peramivir and BCX4161 were discovered using structure based drug design, a proven approach to developing potent and selective inhibitors of enzymes involved in disease. With the recent progress in BioCryst’s hereditary angioedema and peramivir influenza development programs, it is an exciting time to join its Board of Directors,” commented Dr. Cohen.
Please see disclaimer on the MissionIR website
http://www.missionir.com/disclaimer.html
